中文

News & Events

CROs dMed and Clinipace Merge to Accelerate Customer Success2021-04-28

The combined Company will provide full-service CRO services to meet needs of global fast-moving biotech, pharma and medical device companies, and to accelerate the delivery of innovative solutions to p...

Read More

Innoforce and dMed Collaborate to Accelerate the Development of Innovative Therapeutics2021-03-02

Innoforce, a biopharmaceutical innovation enabling platform and PDMO (Partner Development and Manufacturing Organization), and dMed, a clinical CRO with strong presence in China and the US - the world’...

Read More

dMed Completed a US$100 Million Series C Financing2020-12-17

Shanghai, China, Dec. 17th , 2020-- dMed, the clinical CRO with strong presence in China and the US, the world’s two largest pharmaceutical markets and drug development sites, announced today its succe...

Read More

Genetron Health and dMed Announce Partnership Agreement2020-09-17

BEIJING, September 16, 2020 – Genetron Holdings Limited (“Genetron Health” or the “Company”) (Nasdaq: GTH), a leading precision oncology company in China that specializes in offering molecular profilin...

Read More

APEIRON’s respiratory drug product to start pilot clinical trial to treat coronavirus disease COVID-1...2020-05-28

APEIRON Biologics AG, a biotechnology company with an approved product on the market as well as a broad preclinical and clinical pipeline, today announced the launch of a Pilot investigator-initiated c...

Read More

dMed and GenScript signed strategic agreement2020-04-20

dMed Biopharmaceutical (Shanghai) Co., Ltd., a global CRO based in China, and GenScript ProBio, CDMO business segment of GenScript Biotech Corporation, jointly announce that the parties will integrate ...

Read More

dMed raises nearly US$50 million in Series B financing to strengthen and expand its clinical operatio...2019-10-17

Shanghai, October 16, 2019 ---- dMed Biopharmaceutical Co., Ltd. recently announced completion of a nearly US$50 million Series B financing, led by Vivo Capital and joined by Legend Capital, Qiming Ven...

Read More

Target Health and dMed Biopharmaceuticals Join Forces to Help Western and Chinese Biopharma and Devic...2019-06-26

SHANGHAI and NEW YORK, June 24, 2019 /PRNewswire/ -- Target Health Inc. and dMed Biopharmaceuticals Company Limited have joined forces to help Western and Chinese biopharma and device companies capital...

Read More

China:
298 Xiangke Road, 3/F, 301-305, Zhangjiang Hi-Tech Park, Pudong, Shanghai 201210, China
Tel: +86 21 5090 0085 Fax: +86 21 6875 5515
US:
261 Madison Avenue, 24th fl. New York, NY 10016 US
Phone: +1-212-681-2100
沪ICP备16041651号 Copyright © 2016 dMed All Rights Reserved
沪公网安备 31011502005403号